In both spheroid and HepG2 cell models of MASLD, fucoidan alleviates FFA-induced lipid deposition, oxidative stress, and NF-κB-driven inflammatory responses via activation of the PI3K/AKT/Nrf2 signaling pathway (67). Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.